Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

This Study in Healthy Men Tests How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 705564 Affects the Way the Body Breaks Down Midazolam

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 705564
Drug: Midazolam

First Posted Date: 2017-10-30

Last Posted Date: 2022-09-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT03325712

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 894416

First Posted Date: 2017-10-20

Last Posted Date: 2024-03-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT03315936

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis

Phase 3

Completed

Conditions: Lung Diseases, Interstitial

Interventions: Drug: Nintedanib

First Posted Date: 2017-10-18

Last Posted Date: 2024-02-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 444

Registration Number: NCT03313180

Locations: 🇫🇷
HOP Pasteur, Nice, France
🇦🇷
Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Buenos Aires, Argentina
🇦🇷
CEMER-Centro Medico De Enfermedades Respiratorias, Florida, Argentina

and more 156 locations

This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin
Drug: Furosemide
Drug: Probenecid
Drug: Metformin
Drug: Rosuvastatin
Drug: Cimetidine
Drug: Verapamil
Drug: Rifampin

First Posted Date: 2017-10-11

Last Posted Date: 2023-11-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 45

Registration Number: NCT03307252

Locations: 🇩🇪
CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany

Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1015550

First Posted Date: 2017-10-04

Last Posted Date: 2017-12-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT03302078

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body

Phase 1

Completed

Conditions: Healthy
Renal Insufficiency

Interventions: Drug: BI 1467335

First Posted Date: 2017-10-04

Last Posted Date: 2021-06-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT03302091

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in Spain

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: NOAC

First Posted Date: 2017-09-18

Last Posted Date: 2020-02-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1008

Registration Number: NCT03285373

Locations: 🇪🇸
Hospital Dr. José Molina Orosa, Arrecife, Las Palmas, Spain
🇪🇸
Hospital Infanta Cristina, Badajoz, Spain
🇪🇸
Hospital Universitario de Bellvitge, Hospitalet De Ll (Barcelona), Spain

and more 64 locations

Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: L01 - Antineoplastic agents
Drug: L01X - Other antineoplastic agents
Drug: L01XE - Protein kinase inhibitors
Drug: L01XE31 - Nintedanib
Drug: L - Antineoplastic and immunomodulating agents

First Posted Date: 2017-09-13

Last Posted Date: 2019-08-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 172

Registration Number: NCT03281200

Locations: 🇪🇸
Dynamic solutions, Barcelona, Spain

This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357

Phase 1

Completed

Conditions: Psoriasis
Healthy

Interventions: Drug: Placebo
Drug: BI 730357
Drug: Midazolam

First Posted Date: 2017-09-12

Last Posted Date: 2024-12-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 83

Registration Number: NCT03279978

Locations: 🇩🇪
CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: ICS (Inhaled Corticosteroid) (Triple therapy)
Drug: Stiolto Respimat
Drug: LABA (Long-Acting Beta Agonist) (Triple therapy)
Drug: LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)

First Posted Date: 2017-08-29

Last Posted Date: 2022-06-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 714

Registration Number: NCT03265145

Locations: 🇺🇸
Aureus Medical Group, Inc, Rancho Cucamonga, California, United States
🇺🇸
HealthCare Partners, Commerce, California, United States
🇺🇸
Advanced Research for Health Improvement, LLC, Naples, Florida, United States

and more 83 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy